Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

NCT07283965 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

15000

Enrollment

OTHER

Sponsor class

Conditions

Chronic B-cell Malignancies
BTK Inhibitors
Cardiovascular Diseases

Interventions

DRUG: Zanubrutinib
DRUG: Acalabrutinib

Sponsor

University Hospital, Caen